Now the only corneal implant company with intellectual property for
near-vision correction with a powered micro-lens
Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced that on August 2, 2016, its
wholly-owned subsidiary, Presbia Ireland, Ltd., completed the purchase
of the assets of Neoptics AG ("Neoptics"), including its intellectual
"The acquisition of Neoptics' assets, including its patent portfolio,
consolidates the principal intellectual property (‘IP') and ‘know-how'
underpinning the use of an optically powered micro-lens for the
correction of presbyopia (near-vision loss), a condition affecting 1.8
billion people globally. This consolidation of IP and know-how from
Presbia and Neoptics has also created a patent protected platform to
deploy our ‘micro-lens' technology into solutions for vision problems
beyond presbyopia, significantly expanding our addressable market into
the future," said Todd Cooper, President and CEO of Presbia.
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release, and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160822005027/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media